[1] Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Respir Crit Care Med. 2017;195(5):557–582.
[2] López-Campos JL, Tan W, Soriano JB. Global burden of COPD [ J ].Respirology, 2016,21 ( 1 ) : 14 -23 .
[3] Fang X,Wang X, Bai C.COPD in China:the burden and importance of proper management[J]. Chest, 2011, 139(4): 920-929.
[4]Zhong N, Wang C, Yao W, et al. Prevalence of chronic obstructive pulmonary disease in China:a large,population-based survey[J].Am J Respir Crit Care Med,2007,176(8):753760.
[6] GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388: 1545–602.
[7] Chen Wang, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross- sectional study [J]. Lancet, 2018, published online.
[8] Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176(6): 532–555.
[9] Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12): 1128–1138.
[10] Agusti A, Calverley P, Celli B, et al. Characterization of COPD heterogeneity in the ECLIPSE cohort. Respir Res. 2010;11:122.
[11] Han MK, Agusti A, Calverley PM, et al. Chronic obstructive pulmonary disease phenotypes. Am J Respir Crit Care Med. 2010;182(5): 598–604.
[12] Divo M, Cote C, de Torres JP, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(2):155–161.
[13] Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013; 187(4):347–365.
[14] Soriano JB, Lamprecht B, Ramirez AS, et al. Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2007 and 2011 staging systems: a pooled analysis of individual patient data. Lancet Respir Med. 2015;3(6):443–450.
[15] Goossens LM, Leimer I, Metzdorf N, Becker K, Rutten-van Molken MP. Does the 2013 GOLD classification improve the ability to predict lung function decline, exacerbations and mortality: a post-hoc analysis of the 4-year UPLIFT trial. BMC Pulm Med. 2014;14:163.
[16] Kim J, Yoon HI, Oh YM, et al. Lung function decline rates according to GOLD group in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015;10:1819–1827.
[17] Lange P, Marott JL, Vestbo J, et al. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population [J]. Am J respir Crit Care Med, 2012, 186: 975-981.
[18]Johannessen A, Nilsen RM, Storebø M, et al.Comparison of 2011 and 2007 Global Initiative for Chronic Obstructive Lung Disease guidelines for predicting mortality and hospitalization [J]. Am J Respir Crit Care Med, 2013, 188:51-59.
[19] Soriano JB, Alfageme I, Almagro P, et al. Distribution and prognostic validity of the new Global Initiative for Chronic Obstructive Lung Disease grading classification [J]. Chest, 2013,143:694-702.
[20] Han MK,Mullerova H,Curran-Everett D,et al.GOLD 2011 disease severity classification in COPDgene: a prospective cohort study[J].Lancet Respir Med,2013,1( 1) : 43-50.
[22] Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (updated 2016)[EB/OL]. (2016-01) [2016-04-05]. http://www.goldcopd.org.
[23] Halpin DM, Decramer M, Celli B, et al. Exacerbation frequency and course of COPD[J]. Int J Chron Obstruct Pulmon Dis. 2012;7:653-61.
[24] Bestall JC, Paul EA, Garrod R, et al.Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease[J]. Thorax 1999, 54(7):581-586.
[25] Jones PW, Harding G, Berry P, et al.Development and first validation of the COPD Assessment Test[J]. Eur Respir J 2009,34(3):648-654.
[26] Agusti A, Edwards LD, Celli B, et al. Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. Eur Respir J. 2013;42(3):636–646.
[27] Sahadevan A, Cusack R, O’Kelly B, Amoran O, Lane SJ. The Value of the combined assessment of COPD in accurate characterization of stable COPD. Ir Med J. 2016;109(1):338–340.
[28] Tudoric N, Koblizek V, Miravitlles M, et al. GOLD 2017 on the way to a phenotypic approach? Analysis from the phenotypes of COPD in central and eastern Europe (POPE) cohort. Eur Respir J. 2017;49(4): 1602518.
[29]Nizankowska-Mogilnicka E1, Mejza F, Buist AS, et al. Prevalence of COPD and tobacco smoking in Malopolska region--results from the BOLD study in Poland[J]. Pol Arch Med Wewn. 2007 Sep;117(9):402-10.
[30]Eisner MD, Blanc PD, Omachi TA, et al. Socioeconomic status, race and COPD health outcomes[J]. J Epidemiol Community Health. 2011 Jan;65(1):26-34.
[31]Santibanez M, Garrastazu R, Ruiz-Nuñez M, et al. Predictors of hospitalized exacerbations and mortality in chronic obstructive pulmonary disease. PLoS One. 2016;11(6):e0158727.
[32] Gudmundsson G, Ulrik CS, Gislason T, et al. Long-term survival in patients hospitalized for chronic obstructive pulmonary disease: a prospective observational study in the Nordic countries. Int J Chron Obstruct Pulmon Dis. 2012;7:571–576.
[33]Landis SH, Muellerova H, Mannino DM, et al. Continuing to confront COPD international patient survey: methods, COPD prevalence, and disease burden in 2012–2013. Int J Chron Obstruct Pulmon Dis. 2014;9: 597–611.
[34] Kohansal R, Martinez-Camblor P, Agustí A, et al. The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort. Am J Respir Crit Care Med. 2009;180(1):3–10.
[35]Burney P, Jithoo A, Kato B, et al; Burden of Obstructive Lung Disease (BOLD) Study. Chronic obstructive pulmonary disease mortality and prevalence: the associations with smoking and poverty a BOLD analysis. Thorax. 2014;69(5):465–473.
[36] lina sun, Yahong Chen et al. Changes in definition lead to changes in the clinical characteristics across COPD categories according to GOLD 2017: a national crosssectional survey in China. International Journal of COPD 2017:12 3095–3102.
[37] Drivenes E, Ostrem A, Melbye H. Predictors of ICS/LABA prescribing in COPD patients: a study from general practice[J].BMC Fam Pract. 2014 Mar 5;15:42.
[38] Thomas M, Radwan A, Stonham C, et al. COPD exacerbation frequency, pharmacotherapy and resource use: an observational study in UK primary care[J]. COPD. 2014 Jun;11(3):300-9.
[39] Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD[J]. N Engl J Med. 2014 Oct 2;371(14):1285-94.